Driehaus Capital Management’s Cardlytics CDLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-44,814
Closed -$6.49M 382
2024
Q1
$6.49M Buy
+44,814
New +$3.78M 0.06% 265
2021
Q3
Sell
-20,216
Closed -$25.7M 398
2021
Q2
$25.7M Sell
20,216
-8,969
-31% -$10.1M 0.34% 92
2021
Q1
$32M Buy
29,185
+4,540
+18% +$5.99M 0.47% 54
2020
Q4
$35.2M Buy
24,645
+8,689
+54% +$9.27M 0.57% 46
2020
Q3
$11.3M Sell
15,956
-8,857
-36% -$6.44M 0.23% 122
2020
Q2
$17.4M Buy
24,813
+9,628
+63% +$5.56M 0.42% 70
2020
Q1
$5.31M Sell
15,185
-22,227
-59% -$15.7M 0.18% 138
2019
Q4
$23.5M Buy
37,412
+569
+2% +$278K 0.63% 37
2019
Q3
$12.3M Buy
36,843
+12,100
+49% +$3.88M 0.4% 66
2019
Q2
$6.43M Buy
+24,743
New +$4.95M 0.2% 133
2018
Q4
Sell
-30,037
Closed -$7.52M 418
2018
Q3
$7.52M Buy
30,037
+8,196
+38% +$1.76M 0.23% 136
2018
Q2
$4.75M Buy
+21,841
New +$4.04M 0.16% 179

Other funds holding CDLX

Driehaus Capital Management's CDLX Position: Q2 2024 in Review

Driehaus Capital Management sold out of Cardlytics (CDLX) in Q2 2024, closing a stake of 44,814 shares — an estimated $6.49M sold.

Driehaus Capital Management first reported a position in CDLX in Q2 2018 and held it in 12 quarters. The position peaked at $35.2M in Q4 2020. 127 funds tracked by Wall St. Rank hold CDLX as of Q2 2024.

  • Driehaus Capital Management reported no remaining Cardlytics position as of Q2 2024 after selling out during the quarter.
  • Driehaus Capital Management sold 44,814 Cardlytics shares in Q2 2024, an estimated $6.49M.
  • Driehaus Capital Management first reported a position in Cardlytics in Q2 2018 and held it in 12 quarters.
  • Driehaus Capital Management's Cardlytics position peaked at $35.2M in Q4 2020.
  • 127 funds tracked by Wall St. Rank held Cardlytics as of Q2 2024.

Based on Driehaus Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.